Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 4/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.48 |
| ▸ | PRKACA | P17612 | 3/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | PRKX | P51817 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.48 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.42 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21828245 | 1.00 | ROCK1 (0.48) | ROCK1ROCK2PRKG1PKN2CLK4 | |
| SCHEMBL3335417 | 0.88 | ROCK1 (0.56) | ROCK1ROCK2PRKG1PKN2CLK4 | |
| SCHEMBL3335493 | 0.84 | EPHX2 (0.41) | ROCK1ROCK2PRKACAAKT1AKT2 | |
| SCHEMBL1530262 | 0.82 | AKT3 (0.46) | ROCK1ROCK2PRKACARPS6KB1AKT1 | |
| SCHEMBL14114746 | 0.82 | AKT3 (0.46) | ROCK1ROCK2PRKACARPS6KB1AKT1 | |
| SCHEMBL1529767 | 0.80 | AKT1 (0.62) | ROCK1ROCK2PRKACAGSK3BRPS6KB1 | |
| SCHEMBL3335485 | 0.80 | ROCK1 (0.49) | ROCK1ROCK2PRKG1PKN2CLK4 | |
| SCHEMBL1529570 | 0.79 | AKT1 (0.52) | ROCK1ROCK2PRKACAGSK3BRPS6KB1 | |
| SCHEMBL3329027 | 0.79 | CTSB (0.53) | ROCK1ROCK2PRKG1PKN2CLK4 | |
| SCHEMBL3335497 | 0.78 | ROCK1 (0.49) | ROCK1ROCK2PRKG1PKN2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | disclosed |
| EP-3024457-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015013581-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| WO-2008121786-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | ROCK1 1875/4885ROCK2 2335/4885PRKG1 3967/4885 |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | PI4KB, AKT3, AKT2 | ROCK1 414/4885ROCK2 505/4885PRKG1 1192/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | ROCK1 1421/4885ROCK2 2328/4885PRKG1 3803/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | ROCK1 1875/4885ROCK2 2335/4885PRKG1 3967/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | ROCK1 2034/4885ROCK2 2762/4885PRKG1 4878/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | ROCK1 1421/4885ROCK2 2328/4885PRKG1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.